Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum
- PMID: 26574016
- PMCID: PMC4750710
- DOI: 10.1128/AAC.01370-15
Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum
Abstract
Pyrazinamide (PZA) is one of only two sterilizing drugs in the first-line antituberculosis regimen. Its activity is strongly pH dependent; the MIC changes by several orders of magnitude over a range of pH values that may be encountered in various in vivo compartments. We recently reported selective inactivity of PZA in a subset of C3HeB/FeJ mice with large caseous lung lesions. In the present study, we evaluated whether such inactivity was explained by poor penetration of PZA into such lesions or selection of drug-resistant mutants. Despite demonstrating similar dose-proportional PZA exposures in plasma, epithelial lining fluid, and lung lesions, no dose response was observed in a subset of C3HeB/FeJ mice with the highest CFU burden. Although PZA-resistant mutants eventually replaced the susceptible bacilli in BALB/c mice and in C3HeB/FeJ mice with low total CFU burdens, they never exceeded 1% of the total population in nonresponding C3HeB/FeJ mice. The selective inactivity of PZA in large caseous lesions of C3HeB/FeJ mice is best explained by the neutral pH of liquefying caseum.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Figures




Similar articles
-
Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.Antimicrob Agents Chemother. 2015 Dec 7;60(2):1091-6. doi: 10.1128/AAC.02637-15. Print 2016 Feb. Antimicrob Agents Chemother. 2015. PMID: 26643352 Free PMC article.
-
Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.Dis Model Mech. 2015 Jun;8(6):603-10. doi: 10.1242/dmm.019513. Epub 2015 Mar 30. Dis Model Mech. 2015. PMID: 26035868 Free PMC article.
-
High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.Antimicrob Agents Chemother. 2016 Jun 20;60(7):4197-205. doi: 10.1128/AAC.03085-15. Print 2016 Jul. Antimicrob Agents Chemother. 2016. PMID: 27139472 Free PMC article.
-
Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli.Int J Mycobacteriol. 2017 Jul-Sep;6(3):213-221. doi: 10.4103/ijmy.ijmy_85_17. Int J Mycobacteriol. 2017. PMID: 28776518 Review.
-
Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.Trends Pharmacol Sci. 2019 Dec;40(12):930-940. doi: 10.1016/j.tips.2019.10.005. Epub 2019 Nov 6. Trends Pharmacol Sci. 2019. PMID: 31704175 Free PMC article. Review.
Cited by
-
A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.Clin Infect Dis. 2016 Nov 1;63(suppl 3):S75-S79. doi: 10.1093/cid/ciw472. Clin Infect Dis. 2016. PMID: 27742637 Free PMC article. Review.
-
Pyrazinamide Susceptibility Is Driven by Activation of the SigE-Dependent Cell Envelope Stress Response in Mycobacterium tuberculosis.mBio. 2021 Feb 22;13(1):e0043921. doi: 10.1128/mbio.00439-21. Epub 2022 Feb 1. mBio. 2021. PMID: 35100871 Free PMC article.
-
Impact of immunopathology on the antituberculous activity of pyrazinamide.J Exp Med. 2018 Aug 6;215(8):1975-1986. doi: 10.1084/jem.20180518. Epub 2018 Jul 17. J Exp Med. 2018. PMID: 30018074 Free PMC article.
-
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0239821. doi: 10.1128/aac.02398-21. Epub 2022 Mar 22. Antimicrob Agents Chemother. 2022. PMID: 35315690 Free PMC article.
-
Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis.Cell Syst. 2021 Nov 17;12(11):1046-1063.e7. doi: 10.1016/j.cels.2021.08.004. Epub 2021 Aug 31. Cell Syst. 2021. PMID: 34469743 Free PMC article.
References
-
- British Thoracic and Tuberculosis Association. 1976. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet ii:1102–1104. - PubMed
-
- British Thoracic Society. 1984. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest 78:330–336. - PubMed
-
- Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7:6–21. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical